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Abstract
Background: Vimentin is a ubiquitous mesenchymal intermediate filament supporting mechano-structural integrity of
quiescent cells while participating in adhesion, migration, survival, and cell signaling processes via dynamic assembly/
disassembly in activated cells. Soft tissue sarcomas and some epithelial cancers exhibiting ‘‘epithelial to mesenchymal
transition’’ phenotypes express vimentin. Withaferin-A, a naturally derived bioactive compound, may molecularly target
vimentin, so we sought to evaluate its effects on tumor growth in vitro and in vivo thereby elucidating the role of vimentin
in drug-induced responses.
Methods and Findings: Withaferin-A elicited marked apoptosis and vimentin cleavage in vimentin-expressing tumor cells
but significantly less in normal mesenchymal cells. This proapoptotic response was abrogated after vimentin knockdown or
by blockade of caspase-induced vimentin degradation via caspase inhibitors or overexpression of mutated caspase-resistant
vimentin. Pronounced anti-angiogenic effects of Withaferin-A were demonstrated, with only minimal effects seen in non-
proliferating endothelial cells. Moreover, Withaferin-A significantly blocked soft tissue sarcoma growth, local recurrence, and
metastasis in a panel of soft tissue sarcoma xenograft experiments. Apoptosis, decreased angiogenesis, and vimentin
degradation were all seen in Withaferin-A treated specimens.
Conclusions: In light of these findings, evaluation of Withaferin-A, its analogs, or other anti-vimentin therapeutic
approaches in soft tissue sarcoma and ‘‘epithelial to mesenchymal transition’’ clinical contexts is warranted.
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Introduction
Comprising more than 50 histological subtypes, soft tissue
sarcoma (STS) can be classified into two major groups: those with
specific genetic alterations (translocations or point mutations) and
relatively simple karyotypes, and those with complex, unbalanced
aneuploid karyotypes [1], [2], [3], [4], [5], [6]. Enhanced
understanding of the molecular aberrations driving the inception
and progression of several STS subtypes belonging to the first
group (e.g., c-Kit mutations in gastrointestinal stromal tumors
[GIST] or the 17;22 translocation leading to PDGF-B over-
expression in dermatofibrosarcoma protuberans; [DFSP]), has
resulted in clinical applications of effective targeted therapies (e.g.
Imatinib mesylate) with significantly improved outcome [6]. Such
therapeutic advancements are very encouraging and highlight the
need to identify other novel molecular targets in additional STS
subtypes.
The majority of STS belong to the second group harboring
aneuploid karyotypes; this group mainly consists of malignant
fibrous histiocytoma (MFH, also termed unclassified pleomorphic
sarcoma [UPS]), leiomyosarcomas, malignant peripheral nerve
sheath tumors (MPNST), and dedifferentiated or pleomorphic
liposarcomas. While clinical presentation and disease manifesta-
tions vary depending on the specific histological subtype, as a
whole, these complex karyotype STS have a dismal prognosis,
with a 5-year survival rate of less than 50%. Despite initial local
control (achieved by surgery with or without radiation), local
recurrence and systemic spread commonly occur and the lack of
effective therapeutic options in these clinical scenarios is the major
unresolved problem in STS. In contrast to the genetic simplicity of
STS in the first group, the biological and molecular diversity of
complex karyotype STS markedly limits the identification of single
and specific ‘‘oncogenic addiction’’ aberrations. While challeng-
ing, elucidating novel therapies that might have utility for a broad
range of complex karyotype STS is crucial.
Since the early 1960s, plants and microbes have yielded several
useful, naturally derived, small organic molecules possessing anti-
cancer properties [7], [8], [9], [10]. Withania somnifera (ashwa-
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medicine to treat a wide spectrum of disorders [11], [12], [13],
[14], [15]. Withaferin-A (WFA), a highly oxygenated C-28
ergostane-type steroidal lactone, is a bioactive compound isolated
from Withania somnifera. WFA exhibits diverse pharmacologic
activities, including anti-inflammatory, immunomodulatory and
antiangiogenic effects [15], [16], [17], [18]. Several lines of
evidence suggest that WFA has anti-cancer properties, manifested
by directly targeting tumor cells and indirectly impeding [tumor-
associated neovasculature [19], [20]. Recent studies have shown
that WFA suppresses human breast and prostate cancer cells’
growth in vitro and in vivo by inducing marked apoptosis [19], [21],
[22]. WFA-induced cytoskeletal architecture alteration [23], [24],
[25], reactive oxygen species generation [26], [27], mitochondrial
dysfunction [26], and proteosomal inhibition [21] have also been
suggested. Normal, nontumorigenic cells were found to be more
resistant than tumor cells to WFA-induced apoptosis [22];
selectivity for malignant cells while sparing normal cells is a highly
desirable feature of potential anti-cancer therapeutic agents.
The exact mechanisms of WFA action have not been
conclusively defined. Several molecular targets have been
proposed, including the transcription factor NF-kB [28], [29];
the signaling molecule AKT [27]; the proapoptotic molecules
PAR-4, FOXO-3, and Bim [22]; and the proteosomal chymo-
trypsin subunit b5 [21]. A recent study utilized a chemical genetic
and proteomic investigational approach [30], in which a
biotinylated WFA analog was used as a probe to pull down
WFA binding partners in endothelial cells. This strategy resulted
in the identification of vimentin, a type III intermediate filament,
as a novel WFA substrate. Furthermore, WFA-modified vimentin
was found to elicit significant proapoptotic and antiangiogenic
effects, whereas vimentin knockdown resulted in decreased WFA
sensitivity. These experiments offer insight into WFA activity and
highlight the potential utility of vimentin as a novel anti-cancer
therapeutic target.
STS are mesenchymal and therefore all express vimentin,
regardless of their histological subtype. Consequently, it is
plausible that anti-vimentin therapeutic strategies might elicit
anti-STS effects in a broad range of STS. This hypothesis
prompted us to determine the impact of WFA on complex
karyotype STS in vitro and in vivo. We used human cell lines
representing leiomyosarcoma, MPNST, fibrosarcoma, and UPS/
pleomorphic liposarcoma to assess the impact of vimentin on WFA
sensitivity. Our results suggest that STS are highly sensitive to
WFA, an effect that is much more pronounced than in vimentin-
negative epithelial cancers. WFA induces a caspase-dependent
degradation of vimentin, resulting in marked anoikis-independent
apoptosis and STS-associated antiangiogenic effects. The results
strongly support the evaluation of WFA or its analogs as a novel
clinical strategy for patients harboring these devastating
malignancies.
Results
Sarcoma cells are highly sensitive to WFA
To evaluate the effect of WFA on complex karyotype STS we
selected a panel of human STS cell lines representing
fibrosarcoma (HT1080), leiomyosarcoma (SKLMS1), MPNST
(STS26T), and high grade pleomorphic sarcoma/liposarcoma
(PLS-1). This latter cell line has recently been established in our
laboratory (see Data S1 and Figure S1 for further details).
Treatment of the above cells with WFA resulted in a significant
decrease in the number of attached cells and marked morpho-
logical changes, including cell-rounding and nuclear condensa-
tion (Figure 1A). The effects of WFA occurred as early as 2 h
after treatment initiation and were dose- and time-dependent
(Figure S2). Cell growth assays demonstrated a WFA-induced,
dose-dependent decrease in STS cell growth (Figure 1B).
Mean6SD WFA IC50 values (after 24 h of treatment) were
recorded as 0.4 mM60.07, 0.41 mM60.03, 0.37 mM60.12, and
0.53 mM60.1, for HT1080, SKLMS1, STS26T, and PLS-1,
respectively. Similarly, low doses of WFA (0.5 mM) markedly
inhibited STS cell colony formation capacity (Figure 1C). Lastly,
the effect of WFA on STS anchorage independent growth was
investigated. All STS cells evaluated demonstrated a capacity to
grow in soft agar; this growth was abrogated after 24 h of WFA
(0.5 mM) treatment (Figure 1D). Taken together, these data
suggest that human STS cells are highly sensitive to the growth
inhibitory effects of WFA.
WFA induces marked apoptosis in STS cells but less
apoptosis in normal human fibroblasts and myogenic
cells
To evaluate the effect of WFA on STS cell survival, we
conducted Annexin V/FACS analyses. STS cells were treated
with increasing concentrations of WFA (0–5 mM) for 4 h and 24 h;
a significant induction of apoptosis was apparent even within the
short time frame especially when high doses were used (.2.5 mM,
p,0.05; Figure 2A). A dose- and time-dependent increase in
tumor cell apoptosis was observed in all cells tested. Apoptosis
induction was also reflected in the observed increase in activated
caspase 3 and PARP cleavage (Western blot analysis [WB];
Figure 2B).
Next, we evaluated whether WFA-induced apoptosis could be
attributed to tumor cell loss of adhesion and detachment from the
culture plate, resulting in anoikis. Normal human dermal
fibroblasts (NHDF) underwent significant apoptosis when cultured
in suspension, while STS cells were resistant to anoikis and no
significant increase in apoptosis could be observed (Figure 2C).
WFA enhanced apoptosis of both attached and floating STS cells.
WFA-induced apoptosis was further confirmed using transmis-
sion electron microscopy (TEM). Signs of apoptosis, including
chromatin condensation and cytoplasm shrinkage, were evident
within 4 h. After 24 h, marked apoptosis was observed, along with
nuclear membrane loss and cytoplasmic blebbing; these effects
were noticed in both attached and floating STS cells. Floating
necrotic STS cells were also observed (,20–30% of total floating
cells).
Last, we evaluated the effect of WFA on normal mesenchymal
cells (Figure 2E and S3). Primary cultures of NHDF and human
intestinal smooth muscle cells (HISMC) were treated with
increasing doses of WFA for 24 h. Contrary to our observations
in STS cells, decreases in cell number and morphological changes
were evident by microscopy only after high doses of WFA
(.2.5 mM). Mean6SD WFA IC50 values were 3.7 mM60.15 and
3.2 mM60.21 for NHDF and HISMC, respectively. These values
were more than 9 times higher than those observed in STS cells.
Similarly, WFA induced a significantly lower rate of apoptosis in
these normal cells (P,0.05). Taken together, these data suggest
that WFA is a potent proapoptotic compound. STS cells are highly
sensitive to WFA, while normal mesenchymal cells are more
resistant to its effects.
WFA abrogates STS cell migration and invasion
We next evaluated the effect of WFA on STS cell migration and
invasion. STS cells were pretreated with low doses of WFA
(0.5 mM) for 4 h, at which point WFA was washed off carefully
WFA Induces Vimentin Cleavage
PLoS ONE | www.plosone.org 2 April 2010 | Volume 5 | Issue 4 | e10105Figure 1. WFA inhibits STS cell growth. A) WFA treatment (1 mM/24 h) results in marked morphological changes, including cell-rounding and
nuclear condensation, in STS cells; B) MTS assays demonstrate a WFA-induced, dose-dependent decrease in STS cell growth; C) WFA (0.5 mM/24 h)
markedly inhibits STS cell colony formation capacity measured after ten days; D) WFA (0.5 mM/24 h) abrogates STS cell anchorage independent
growth measured after three weeks. Graphs represent the average of three repeated experiments 6SD.
doi:10.1371/journal.pone.0010105.g001
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marked decrease in migration (Figure S4A). In addition, modified
Boyden chambers were used to quantitate the effect of WFA on
migration and invasion. STS cells were pretreated with a low dose
of WFA (0.5 mM) for 4 h. After discontinuation of WFA, cells were
washed and counted; only viable cells were further utilized. WFA
significantly inhibited migration and invasion in all STS cells
examined (P,0.05; Figure S4B).
One potential caveat to these experiments is that the impact
demonstrated might reflect the antiapoptotic or growth-inhibitory
effects of WFA rather than its direct effects on motility and/or
invasion. To address this possibility, in conjunction with the above
Figure 2. WFA induces marked apoptosis in STS cells. A) Annexin-V/FACS analyses demonstrating marked WFA-induced apoptosis in STS cells
(black bars represent 4 h of WFA treatment and gray bars represent 24 h); B) WFA (1 mM/24 hr) induces caspase-3 (Casp-3) cleavage and PARP
activation in STS cells (WB analysis); C) STS cells are resistant to anoikis as compared to normal human dermal fibroblasts (NHDF). WFA (1 mM/24 hr)
induces apoptosis in both attached and floating STS cells; D) Transmission electron microscopy (TEM) photographs depicting STS cell apoptosis (large
arrow–nuclear condensation, small arrow–cytoplasmic blebbing) in response to WFA. Necrosis is demonstrated in floating STS cells; E) NHDF are more
resistant to the effects of WFA (IC50: 3.7 mM60.15) as compared to STS cells. Graphs represent the average of three repeated experiments 6SD.
doi:10.1371/journal.pone.0010105.g002
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(0.5 mM for 4 h) or DMSO (control); at discontinuation of WFA,
cells were washed and counted, and viable cells were re-plated.
Cell counting at the end of the experiment revealed only a small
decrease (,10%) in the number of viable WFA-treated cells
relative to the number of control-treated cells (data not shown).
Together, these results suggest that WFA abrogates STS cell
motility and invasion.
WFA induces vimentin degradation and vimentin
knockdown decreases cells’ sensitivity to WFA
A recent study identified vimentin as the possible WFA
molecular target [30]. Therefore, we evaluated the effect of
WFA on vimentin expression and degradation. WFA treatment
resulted in decreased full-length vimentin levels and increased
expression of vimentin degradation products in all STS cells tested
(Figure 3A). WFA effect on vimentin is dose and time dependent;
high WFA concentrations result in vimentin cleavage after only
4 h of treatment, while vimentin degradation is noticed after 24 h
with lower doses.
To determine whether the effect of WFA on STS cells is at least
partially mediated through vimentin, we elected to use a vimentin
knockdown approach. Anti-vimentin SMARTpool siRNA elicited
a substantial decrease in vimentin expression in SKLMS1 cells
(WB; Figure 3B). Vimentin knockdown per se did not induce
significant apoptosis in STS cells, as compared to mock or non-
targeting siRNA transfection. As expected per the experiments
above, WFA treatment resulted in significant apoptosis in mock
and non-targeting siRNA transfected cells. However, vimentin
knockdown substantially blocked WFA-induced apoptosis. To-
gether, these data suggest that WFA-induced vimentin degrada-
tion is necessary for enhanced therapeutic effect.
To confirm the potential role of vimentin in WFA-induced
apoptosis, we used a rescue experimental approach. Endogenous
vimentin was first knocked down in SKLMS1 cells using anti-
vimentin antisense phosphorodiamidate morpholino oligomers.
These morpholinos target vimentin pre-mRNA, thereby enabling
the forced re-expression of vimentin by transfecting a vimentin
construct resistant to the continuous presence of the morpholino
oligomers. After knockdown, vimentin was forcefully re-expressed
in the cells (WB, Figure 3C); cells were treated with WFA or
DMSO as control and subjected to Annexin V/FACS analysis.
Similar to the results of siRNA knockdown, anti-vimentin
morpholino oligomers treatment significantly blocked WFA-
induced apoptosis. Re-expression of vimentin restored SKLMS1
sensitivity to WFA (Figure 3C).
Both STS cells and normal mesenchymal cells express vimentin.
However, as shown in Figure 2, WFA induces more significant
pro-apoptotic effects in STS cells as compared to normal
mesenchymal cells (i.e. fibroblasts and muscle cells). The previous
published data described above (30) identified WFA to bind to
tetrameric, soluble vimentin. Thus, we sought to evaluate the
levels of this vimentin fraction in normal vs. STS cells. As shown in
Figure 3D, tumor cells express significantly higher levels of soluble,
free vimentin as compared to normal mesenchymal cells. This
finding offers a possible explanation for our observed differential
WFA effects.
WFA-induced vimentin degradation is
caspase-dependent
Vimentin degradation commonly occurs through the activation
of the caspase pathway. To evaluate whether WFA-induced
vimentin degradation is a result of caspase cleavage, we pretreated
STS with Z-VAD (Promega, Madison, WI), a pan-caspase
inhibitor, before WFA therapy (for 24 h). Z-VAD pretreatment
resulted in decreased vimentin degradation in conjunction with
lower levels of both cleaved caspase-3 and activated PARP
(Figure 4A). Furthermore, Z-VAD pretreatment significantly
abrogated WFA-induced apoptosis (after 24 h of WFA treatment)
in STS cells (Figure 4B). Next, after vimentin knockdown using
morpholino oligos, SKLMS1 cells were transfected to express
either wild-type vimentin or vimentin mutated at caspase cleavage
sites (D85N and D259N). WFA (1 mM) induced marked apoptosis
in wild-type vimentin transfected cells in which vimentin
degradation and caspase-3 activation were observed (Figure 4C).
However, we observed a significant decrease in WFA-induced
apoptosis in cells expressing the mutated vimentin, and we noticed
a dramatic decrease in both vimentin degradation and caspase-3
activation (Figure 4C). Taken together, these data suggest a
possible WFA-induced vicious cycle, wherein WFA binding to
vimentin elicits its degradation by caspases and said degradation
results in additional caspase activation and apoptosis.
WFA-induced molecular deregulations are, at least partly,
mediated by vimentin
Several molecular mechanisms have previously been proposed
to underlie WFA anti-tumorigenic effects including inhibition of
AKT phosphorylation [27], abrogation of NF-kB function [20],
[31], and direct proteosomal inhibition [21]. We first sought to
evaluate whether these molecular deregulations occur in STS cells
in response to WFA treatment. We observed a WFA dose- and
time-dependent decrease in pAKT levels, but not total AKT
levels, in STS cells (Figure 5A). Similarly, a dose-dependent
decrease in NF-kB (p65) was also demonstrated, although this
decrease occurred only after 24 h of treatment. NF-kB activity, on
the other hand, was shown to be inhibited early after treatment,
suggesting mechanisms other than decreased NF-kB protein
expression affecting NF-kB activity. In addition, we found a
marked dose- and time-dependent accumulation of ubiquitinated
proteins, supporting WFA-induced proteosomal inhibition in these
cells.
Our results suggest a pivotal role for vimentin in cells’ response
to WFA. Thus, we sought to evaluate whether the effects of WFA
on these diverse pathways can, at least partly, be mediated through
vimentin. SKLMS1 cells were transiently transfected with anti-
vimentin siRNA or non-targeting siRNA and then treated with
WFA. Vimentin knockdown abrogated WFA-induced pAKT
inhibition, NF-kB protein decrease and activity blockade, and
increased levels of protein ubiquitination (Figure 5B). These
experiments provide further evidence that the effects of WFA are
mediated through vimentin and highlight novel potential vimentin
functions.
WFA induces apoptosis in endothelial cells cultured in
STS-conditioned media
Analogous to solid malignancies, STS consist of both tumor and
tumor-associated normal cells; STS growth, migration, and
dissemination depend on cross-talk between these two compart-
ments. STS are generally highly vascular and angiogenic, resulting
in increased metastatic potential. Previous data suggest that WFA
might harbor antiangiogenic properties [17], [30]. To further
expand these initial observations and evaluate the potential
antiangiogenic effects of WFA in the context of the STS
microenvironment, we evaluated the effect of WFA on endothelial
cell grown in regular control medium (lacking angiogenic factors,
mimicking quiescent endothelial cells) and on endothelial cells
WFA Induces Vimentin Cleavage
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ing angiogenic endothelial cells). We used both human endothelial
(HDMEC) and murine endothelial cells (LEC) and observed a
significantly higher WFA-induced growth inhibition in endothelial
cells cultured in STS-CM than in control medium (Mean6SD
WFA IC50: 0.42 mM60.16 vs. 1.4 mM60.04 in HDMEC and
0.38 mM60.09 vs. 2.3 mM60.1 in LEC; P,0.05, Figure 6A).
Similarly, WFA induced higher levels of apoptosis in endothelial
cells grown in STS-CM than in control medium (Figure 6B).
Endothelial cells are mesenchymal in origin and thus express
vimentin, so we evaluated the effect of WFA on vimentin
expression and cleavage in both regular media and STS-CM.
Interestingly, WFA induced significantly higher rates of vimentin
degradation and caspase-3 activation in endothelial cells grown in
STS-CM than in quiescent endothelial cells (Figure 6C). Next, we
evaluated the effect of WFA on endothelial cell migration and
invasion. Similar to the previously described experimental
approach utilized with STS cells, we used viable endothelial cells
pretreated with short-term WFA (4 h) in modified Boyden
chamber assays. As anticipated, STS-CM enhanced endothelial
cell migration and invasion. More important, WFA abrogated
migration and invasion of endothelial cells cultured in STS-CM,
but not that of those grown in regular medium (Figure 6D).
Last, to confirm that the observed WFA antiangiogenic effect
occurs in vivo as well, we performed a Gelfoam angiogenesis assay
Gelfoam sponges were incubated in STS-CM and implanted
subcutaneously into the flanks of SCID mice. Two days after
implantation, mice were treated with i.p. WFA (2 mg/kg; n=4) or
DMSO (n=4) for 10 consecutive days; at the termination of the
study, the Gelfoams were excised and subjected to IHC analysis
(Figure 6E). WFA treatment resulted in a significant decrease in
the mean number of CD31-positive blood vessels compared to
control DMSO treatment (4167.2 vs. 665.3, respectively;
P,0.05). CD-31/TUNEL double staining revealed endothelial
cell apoptosis in WFA-treated mice. These results suggest that
WFA potentially abrogates cell growth, inhibits migration and
invasion, and induces apoptosis in proliferating endothelial cells
within the STS microenvironment.
Epithelial origin cancers’ sensitivity to WFA is enhanced
in cells exhibiting epithelial to mesenchymal transition
(EMT)
Our central hypothesis is that cells expressing vimentin are
expected to demonstrate a higher WFA sensitivity. Unlike STS,
the more common epithelial origin cancers do not naturally
express vimentin. However, substantial data indicate that both
invasion and metastasis may critically depend on the acquisition of
a ‘‘mesenchymal’’ phenotype by the incipient cancer cell [32],
[33], [34]. One of the hallmarks of this epithelial to mesenchymal
transition, is induced vimentin expression. Taking this into
account, we analyzed vimentin expression in a panel of carcinoma
cell lines and evaluated their response to WFA. Three of the cells
(MCF7, HT29, and TMK1) exhibited no vimentin mRNA and
protein expression, and the other two (MDA231 and A549)
expressed vimentin (Figure 7A). Cells expressing vimentin were
significantly more sensitive to WFA than those not expressing
vimentin (Mean6SD WFA IC50 values in MDA231 and A549
cells were 1.3 mM60.42 and 1.8 mM60.37, respectively, and
2.9 mM60.31, 7.8 mM62.34, 3.1 mM60.18 in MCF-7, HT29,
and TMK1 cells, respectively; P,0.05). Similarly, WFA (1 mM for
24 h) elicited a significantly higher apoptotic rate in vimentin-
expressing carcinoma cells (P,0.05; Figure 7B). WB analysis
further revealed vimentin degradation products in MDA231 cells
in conjunction with enhanced cleaved caspase-3 and activated
PARP expression levels (Figure 7C). In contrast, only minimal or
no expression of cleaved caspase-3 and activated PARP was
demonstrated in MCF7 and HT29 cells, respectively. The data
presented here further support the role of vimentin as a WFA
molecular target, suggesting the possible therapeutic efficacy of
WFA on epithelial cancers exhibiting EMT phenotypes.
WFA abrogates STS growth, angiogenesis, recurrence,
and metastasis in vivo
To test the potential in vivo significance of the above
observations, we investigated the effect of WFA on STS growth,
local recurrence, and metastasis using several human STS
xenograft mouse models representing different complex karyotype
STS histological subtypes.
First, we investigated the effect of WFA on leiomyosarcoma
(SKLMS1) and fibrosarcoma (HT-1080) growth in SCID mice. In
a 2-arm study (n=10/group), we compared the effects of WFA
(2 mg/kg) to that of the carrier (DMSO) alone. Previous studies
demonstrated in vivo efficacy and no significant side effects in breast
and prostate cancer xenografts when a WFA dose of 4 mg/kg was
utilized [19]; estimating enhanced sensitivity in STS xenografts,
we selected a lower WFA dose. Therapy was initiated after tumor
establishment, as defined in Methods. The treatment regimen was
highly tolerated; we observed no significant weight loss. WFA
caused significant growth retardation in both tumor types
(Figure 8A); at the termination of the study, mean6SD SKLMS1
tumor volumes were 501.6 mm
36114.2 in the WFA group vs.
1365.7 mm
36155.5 in the control group (P=0.032), and HT1080
tumor volumes were 210 mm
3641.4 vs. 1050.1 mm
3651.9,
respectively (P=0.001). Similarly, WFA treatment significantly
reduced tumor weight. Mean 6 SD tumor weights at the
termination of the study were 779.5 mg6175.4 and
770.6 mg6218.4 in control mice and 230.6 mg664.4 and
211.8 mg694.1 in WFA-treated mice bearing SKLMS1 and
HT1080 xenografts, respectively (P=0.017 and P=0.036;
Figure 8A).
Tumor sections containing viable cells from each treatment
group were selected for IHC studies (Figure 8B). PCNA staining
revealed a significant decrease in tumor cell proliferation (the
mean6SD PCNA scores were 88%610.2% and 73%614.7% in
control tumors and 25%610.2% and 15%66.5% in WFA-treated
tumors of SKLMS1 and HT1080 xenografts, respectively;
Figure 3. WFA induces vimentin degradation and vimentin knockdown decreases cells’ sensitivity to WFA. A) WFA treatment (5 mM/
4 h) results in decreased full-length (FL) vimentin levels and increased expression of vimentin degradation products (VDP) in all STS cells tested. A
WFA dose dependent effect in SKLMS1 cells treated for 4 h is also shown. Vimentin cleavage is noticed secondary to low WFA concentrations after
24 h of treatment; B) Anti-vimentin SMARTpool siRNA (20 nM) elicits a marked decrease in vimentin expression in SKLMS1 cells (WB). Vimentin
knockdown substantially blocks WFA-induced (1 mM/24 hr) apoptosis; C) Endogenous vimentin was first knocked down in SKLMS1 cells using anti-
vimentin antisense phosphorodiamidate morpholino oligomers. After knockdown, vimentin was forcefully re-expressed in the cells (WB). Similar to
the results of siRNA knockdown, anti-vimentin morpholino oligomers significantly blocks WFA-induced (1 mM/24 hr) apoptosis. Re-expression of
vimentin restores SKLMS1 sensitivity to WFA; D) STS cells (SKLMS1 and PLS1) express significantly higher levels of soluble vimentin as compared to
normal mesenchymal cells (smooth muscle cells: HA-SMC and HC-SMC and fibroblasts: NHDF). (NT siRNA = non targeting siRNA, Vim siRNA = anti-
vimentin siRNA smartpool; NT morpholino = non targeting morpholino; Vim KD = vimentin knockdown)
doi:10.1371/journal.pone.0010105.g003
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PLoS ONE | www.plosone.org 7 April 2010 | Volume 5 | Issue 4 | e10105Figure 4. WFA-induced vimentin degradation is caspase-dependent. A) Pretreatement (4 h) of SKLMS1 cells with Z-VAD (a pan-caspase
inhibitor) results in decreased WFA-induced (24 h) vimentin degradation in conjunction with lower levels of both cleaved caspase-3 and activated
PARP; B) Z-VAD (4 h) pretreatment significantly abrogates WFA-induced (24 h) apoptosis in SKLMS1 cells; C) Vimentin knocked down SKLMS1 cells
were transfected to express either wild-type vimentin or vimentin mutated at caspase cleavage sites (D85N and D259N). WFA (1 mM/24 hr) induces
marked apoptosis in wild-type vimentin transfected cells in which vimentin degradation and caspase-3 activation can be detected (WB). However, a
significant decrease in WFA-induced apoptosis in cells expressing the mutated vimentin, is noticed as well as a decrease in both vimentin
degradation and caspase-3 activation. (WT Vim= wild type vimentin; Mut Vim = mutated vimentin; Vim FL = full length vimentin; VDP = vimentin
degradation products)
doi:10.1371/journal.pone.0010105.g004
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PLoS ONE | www.plosone.org 8 April 2010 | Volume 5 | Issue 4 | e10105Figure 5. WFA-induced molecular deregulations are, at least partly, mediated by vimentin. A) WFA treatment induces a dose- and time-
dependent decrease in pAKT without effect on total AKT. Similarly, a dose-dependent decrease in NF-kB (p65) protein expression is also seen,
although this decrease occurs only after 24 h of treatment. NF-kB activity in PLS1 cells, as depicted in graphs representing luciferase reporter assay
results, is shown to be inhibited early after treatment (4 h). A marked dose- and time-dependent accumulation of ubiquitinated proteins is also
shown; B) Vimentin knockdown in SKLMS1 cells abrogates WFA (2.5 mM/24 h)-induced pAKT inhibition, NF-kB protein decrease, and increased levels
of protein ubiquitination. Similarly, vimentin knockdown blocks WFA (1 mM/4 h)-induced decrease in NF-kB activity. Graphs represent the average of
three repeated experiments 6SD.
doi:10.1371/journal.pone.0010105.g005
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cant apoptosis in WFA-treated cells (mean6SD TUNEL scores
were 261 and 562 in control tumors and 77613 and 63610 in
WFA-treated tumors bearing SKLMS1 and HT1080 xenografts,
respectively; P=0.001 and P=0.017). Furthermore, WFA in-
duced a significant decrease in tumor-associated blood vessels, and
small collapsed CD31-positive vessels were detected in the treated
tumors (mean6SD microvascular density [MVD] was 38.2617.1
and 64.3621.6 in control tumors and 11.467.8 and 6.165.8 in
WFA-treated tumors of SKLMS1 and HT1080 xenografts,
respectively; P=0.021 and P,0.0001). CD31/TUNEL double
immunofluorescence analysis identified apoptotic endothelial cells
in WFA-treated tumors. WB analysis of tissue samples revealed
vimentin degradation and caspase-3 activation in WFA-treated
tumors, confirming the effects of WFA on vimentin in vivo
(Figure 8C).
One of the major clinical challenges in STS management is
successfully interdicting their enhanced propensity for local
recurrence. To evaluate whether WFA can inhibit STS local
failure, we established SKLMS1 tumor xenografts and surgically
enucleated (macroscopically resected) them when the tumor size
reached an average of 1.5 cm in diameter. Two days after tumor
resection, mice were allocated to 1 of 2 groups as previously
described and observed for tumor recurrence (Figure 8D). Six of 7
mice (86%) in the control group developed tumor recurrence
within approximately 3 weeks of surgery, whereas only 2 of 8
(25%) WFA-treated mice experienced local failure within this
same time frame (P=0.02). These results suggest that adjuvant
WFA treatment might be potentially useful in abrogating or
delaying STS local recurrence.
To evaluate the effect of WFA on metastatic growth, we utilized
an experimental MPNST lung metastasis model. STS26T cells
were injected into the SCID mice tail veins. Treatment was
initiated 10 days after injection, a time point at which 95–100% of
mice usually harbor established lung metastasis. The mice were
treated with WFA or DMSO as control (n=10/group) for two
weeks. At the termination of the study, the lungs were harvested,
weighed, and evaluated for metastases. All control mice exhibited
numerous large lung metastases that almost completely replaced
the lung parenchyma. In contrast, WFA-treated mice exhibited
markedly fewer small lung nodules (Figure 8E). Macroscopic
findings were confirmed by H&E staining, demonstrating large
lung tumor deposits in control mice and smaller, microscopic
lesions in WFA-treated mice. The average6SD lung weight of
control mice (635.6 mg6119.1) was significantly higher than that
of WFA-treated mice (329.1 mg6114.4; P=0.011).
These data demonstrate the pronounced and broad anti-STS
effects of WFA in vivo. The models utilized represent clinically
relevant STS-related scenarios and incorporate a diverse panel of
STS histological subtypes. These findings recapitulate the results
obtained in vitro, suggesting that WFA treatment results in vimentin
degradation and marked apoptosis, targeting both tumor cells and
sarcoma-associated endothelial cells. Taken together, our findings
strongly support further evaluation of WFA and/or its analogs in
STS clinical contexts.
Discussion
Vimentin is one of the most widely expressed mammalian
intermediate filament proteins. Its expression commences at E8.5
of mouse development in the primary mesenchymal cells forming
the primitive streak [35]. In adults, vimentin is present in all
mesenchymal cells and tissues [36] and is frequently used as a
marker of differentiation. Like other intermediate filaments, the
vimentin network, spreading from the nucleus to the plasma
membrane, is believed to act as a scaffold, providing cellular
mechano-structural support and thereby maintaining cell and
tissue integrity [37].
Studies in genetically engineered mice have previously
demonstrated that the vimentin 2/2 phenotype is rather mild
and that the structural role of vimentin is possibly redundant and
compensated via other cellular components [38]. This observa-
tion is of potential importance if vimentin is to be considered an
antitumor molecular therapeutic target as suggested by the results
presented here. Moreover, an increasing body of evidence
suggests that under cellular stress, functions of vimentin extend
well beyond its mechanical and structural properties [39] to
include demonstrable roles in adhesion, migration, survival, and
cell signaling [40], [41], [42], [43], [44], [45], [46], [47], [48].
For example, vimentin plays a key role in endothelial cell
adhesion by regulating integrin functions [49], and it has also
been identified as a major contributor to leukocyte transmigration
[50], [51].
While the exact mechanisms of vimentin function are not yet
fully elucidated, the unique properties described above have been
attributed to the dynamic disassembly/assembly and spatial
reorganization of vimentin in response several stimuli [35], [52],
[53], [54], [55], [56], [57], [58], [59], [60]. Post-translation
modifications of vimentin, specifically phosphorylation, are
thought to regulate the dynamic states of vimentin [55], [61],
[62], [63], [64], [65], [66], [67]. Vimentin contains a highly
complex phosphorylation pattern involving a multitude of kinase-
specific sites and has been recognized as a substrate for several
kinases, including Rho kinase, protein kinase C (PKC), cGMP
kinase, Yes kinase, Raf-1 kinase, PAK kinase, and Aurora B kinase
[68], [69], [70], [71], [72], [73]. Phosphorylation enhances the
disassembly of vimentin into nonfilamentous (monomeric, dimeric,
and tetrameric) particles, shifting the equilibrium between
polymeric and depolymerized vimentin [74]. For example, in
cultured smooth muscle cells, contractile stimulation triggers
vimentin phosphorylation by PAK, resulting in partial disassembly
and spatial reorientation of vimentin [75], [76]. In addition,
external stress results in vimentin depolymerization in fibroblasts
secondary to Rho kinase phosphorylation [70], [77]. The resulting
pool of free vimentin may mediate its effects on motility, adhesion,
cell signaling, and cell survival. For example, after axonal injury, a
soluble form of vimentin has been shown to facilitate activated
MAPK transport to the nucleus [78]. Similarly, phosphorylated,
disassembled vimentin has been demonstrated to enhance the
recycling of integrins subjected to endocytosis to the plasma
membrane during cell migration [67].
Figure 6. WFA induces apoptosis in endothelial cells cultured in STS-conditioned media. A) A significantly higher rate of WFA-induced
(24 h) growth inhibition is seen in endothelial cells (human dermal microvessel endothelial cells–HDMEC and murine lung endothelial cells–LEC)
cultured in STS conditioned medium (CM) than in control regular medium (RM); B) WFA(1 mM/24 hr) induces higher levels of apoptosis in endothelial
cells grown in STS-CM than in control medium; C) WFA (1 mM/24 hr) induces significantly higher rates of vimentin degradation and caspase-3
activation in endothelial cells grown in STS-CM than in quiescent endothelial cells; D) WFA (1 mM) abrogates migration and invasion of endothelial
cells cultured in STS-CM; E) WFA (2 mg/kg) results in a significant decrease in the mean number of CD31-positive (red) blood vessels compared to
control DMSO treatment in an in vivo gelfoam assay. CD-31(red)/TUNEL(green) double staining reveals endothelial cell apoptosis in WFA-treated
mice. Graphs represent the average of three repeated experiments 6SD. (Vim FL = full length vimentin; VDP = vimentin degradation products)
doi:10.1371/journal.pone.0010105.g006
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under quiescent conditions, polymeric vimentin maintains cellular
integrity, a physiological, ‘‘traditional’’ role that, without vimentin,
might be compensated (or performed) by other intermediate
filaments. However, under stress and stimulatory conditions,
vimentin phosphorylation impairs the steady state of vimentin in
favor of increased free, depolymerized vimentin; this ‘‘activated’’
vimentin pool in turn mediates the ‘‘nontraditional’’ vimentin
functions.
‘‘Hijacking’’ of normal physiological processes is a hallmark of
cancer. The plethora of described functions of vimentin might
contribute to the protumorigenic, prometastatic properties of
vimentin-expressing cancer cells, i.e., STS and epithelial cancers
featuring EMT [32], [33], [34]. Several studies have demonstrated
that vimentin expression levels correlate with poor outcome in
epithelial-origin cancers [79], [80], [81], [82], [83]. Recently
vimentin knockdown was reported to inhibit vimentin-expressing
epithelial cell migration and adhesion [84]. While not previously
Figure 7. Epithelial origin cancers’ sensitivity to WFA is enhanced in cells exhibiting epithelial to mesenchymal transition (EMT). A)
WFA-induced growth inhibition corresponds to vimentin expression level in epithelial origin cancer cells; B) WFA (1 mM for 24 h) elicits a significantly
higher apoptotic rate in vimentin-expressing carcinoma cells; C) WB analysis demonstrating vimentin degradation MDA231 cells in conjunction with
enhanced cleaved caspase-3 and activated PARP expression levels. In contrast, only minimal or no expression of cleaved caspase-3 and activated
PARP are seen in the vimentin-negative MCF7 and HT29 cells. Graphs represent the average of three repeated experiments 6SD. (Vim FL = full
length vimentin; VDP = vimentin degradation products)
doi:10.1371/journal.pone.0010105.g007
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PLoS ONE | www.plosone.org 12 April 2010 | Volume 5 | Issue 4 | e10105Figure 8. WFA abrogates STS growth, angiogenesis, recurrence, and metastasis in vivo. A) WFA (2 mg/kg) significantly inhibits STS local
growth and tumor weight; B) WFA treatment decreases tumor cell proliferation (PCNA), enhances apoptosis (TUNEL), and inhibits STS associated
angiogenesis (CD31). CD31 (red)/TUNEL (green) double immunofluorescence analysis demonstrating apoptotic endothelial cells in WFA-treated
tumors; C) WB analysis of tissue samples demonstrating vimentin degradation and caspase-3 activation in WFA-treated tumors; D) Kaplan Meier
curves demonstrating a statistically significant (P=0.02) delay in SKLMS1 local recurrence in WFA treated mice (black curve) compared to control
(gray curve); E) Control mice (DMSO treated) exhibit numerous large MPNST lung metastases almost completely replacing the lung parenchyma. In
contrast, WFA-treated mice exhibit markedly fewer microscopic small lung nodules (circle). WFA treatment significantly decreases average lung
weights as compared to controls (box plots). (Vim FL = full length vimentin; VDP = vimentin degradation products).
doi:10.1371/journal.pone.0010105.g008
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known to express a multitude of activated kinases, the steady state
of vimentin will be shifted toward the presence of a large pool of
free, depolymerized ‘‘activated’’ vimentin. Our results support this
hypothesis, demonstrating a significantly higher level of soluble
vimentin in tumor vs. normal cells. In that case, ‘‘activated’’
vimentin might be a novel, unique anti-cancer therapeutic target,
as supported by our findings described here.
WFA was previously shown to bind to tetrameric vimentin at a
unique pocket between the pair of head-to-tail a-helical dimers
[30]. It is possible that free, soluble vimentin—rather than
polymerized, filamentous vimentin—is the target of WFA. This
notion might offer an explanation for our observation that WFA
induces an effect that is selective to vimentin-expressing cancer
cells and proliferating stimulated tumor-associated endothelial cells
but only minimally affects normal mesenchymal cells under
quiescent conditions. Our findings further support previous data
demonstrating WFA selectivity to cancer cells rather than normal
cells [19], [85], a property of significant potential clinical
relevance.
The potential utility of vimentin as an anti-cancer molecular
therapeutic target is highlighted by recent findings suggesting
marked proapoptotic effects induced by vimentin cleavage [86].
Vimentin undergoes rapid caspase-induced proteolysis (at
caspase cleavage sites: Asp85, Asp259, and Asp429; [86] upon
diverse proapoptotic stimuli, including ionizing radiation, Fas,
TRAIL, TNFa, and tamoxifen administration [87], [88], [89].
This cleavage results in an irreversible disruption of vimentin
filaments that precedes the dramatic reorganization of the
cytoskeleton that typifies apoptotic cell death. It is possible that
vimentin degradation and collapse contribute to many of the
morphological manifestations of apoptosis, including cellular
rounding, nuclear condensation, and packaging of the debris of
dying cells into apoptotic bodies. Furthermore, vimentin
degradation releases potential proapoptotic proteolytic fragments
that can markedly enhance apoptosis [86]. For example, the
generation of a short N-terminal cleavage product (amino acids
1–85) has been shown to play an active proapoptotic role;
overexpression of this peptide in MCF-7 cells resulted in
significant caspase-dependent apoptosis [86]. A positive feedback
loop is suggested, whereby activated caspases induce the
cleavage of vimentin and these cleavage products in turn
activate caspases to amplify apoptosis.
Our study further demonstrates the role of vimentin in
apoptosis. WFA was previously shown to induce marked apoptosis
in cancer cells [18], [19], [22], [26], [85], [90]. Data presented
here validated these findings and demonstrated that WFA-induced
apoptosis is significantly more pronounced in vimentin-expressing
cells. Furthermore, vimentin knockdown, as well as inhibition of
vimentin degradation (using either caspase inhibition or overex-
pression of caspase-resistant vimentin), abrogated WFA-induced
apoptosis. Taken together, these findings suggest that vimentin
may function as a potential double-edged sword for STS and other
vimentin-expressing cancers. On one hand, vimentin’s inherent
properties elicit protumorigenic, prometastatic effects; on the other
hand, its cleavage strongly incites proapoptotic signals. Therefore,
further evaluation of vimentin as a molecular therapeutic target is
warranted.
Whether vimentin is the exclusive target of WFA cannot be
ascertained based on the current study, and several additional
WFA-induced molecular mechanisms have been previously
demonstrated [17], [18], [20], [22]. However, the role of vimentin
in WFA-induced toxicity is strongly supported and is reflected in
the marked sensitivity of vimentin-expressing cells to the
compound when compared to other cancer cells (as evidenced
by IC50 values in the nanomolar vs. micromolar range,
respectively). Furthermore, it is also possible that several previously
identified WFA-induced molecular effects, such as decreased AKT
phosphorylation [18], reduced NF-kB activity [31], and proteo-
somal inhibition [21], are at least in part mediated by vimentin
degradation, as reflected in our study. The mechanisms of
vimentin effect on these pathways are unknown and merit further
consideration.
The relative rarity of STS, compounded by its clinical and
molecular diversity, has significantly hampered progress in
developing improved therapeutic approaches for this cohort of
devastating malignant neoplasms. To our knowledge, the studies
presented here are the first to demonstrate the potent anti-STS
effects of WFA in vitro and in vivo. We observed these effects in a
panel of diverse human complex karyotype STS histological
subtypes, suggesting the potential broad applicability of WFA in
STS. Furthermore, these effects were independent of p53
mutational status; three of the cell lines tested (SKLMS1, STS26T,
and PLS1) harbor mutated p53, whereas HT1080 exhibits wild
type p53. This finding is important because p53 mutations are
very common in STS, and p53-mutated STS are more
therapeutically resistant [91].
Lastly, considering the marked angiogenic nature of STS, our
data further supports the antiangiogenic effects of WFA, thereby
buttressing previously published studies [17], [30], [92] while
suggesting the potential for significant clinical relevance. The
likelihood of greater genetic stability in co-opted endothelial cells
than in STS tumor cells per se would hopefully lead to their being
less likely to acquire chemoresistance during the toxic stress
selection of such therapies, raising the possibility that therapies
targeting both sarcoma cells and their tumor-associated endothe-
lial cells may lead to improved STS treatment.
Methods
Cell culture and reagents
Human STS cell lines SKLMS1 (leiomyosarcoma) and HT1080
and were purchased from the American Type Culture Collection
(ATCC); ST26T cell line (malignant peripheral nerve sheath
tumor) was a kind gift from Dr. Steven Porcelli (Albert Einstein
College of Medicine, NY, NY; [93]). PLS1 cell line was established
in our laboratory (see Data S1 for further information); This study
was conducted with institutional review board (IRB) approval
from the University of Texas M.D.Anderson Cancer Center and
with patient written informed consent. The epithelial cancer cell
lines MDA-231 and MCF7 (breast cancer); A549 (lung cancer),
HT29 (colon cancer), and TMK1 (gastric cancer) were purchased
from ATCC. LEC (murine lung endothelial cells) have been
described previously [94]; HDMEC (human dermal microvascular
endothelial cells) and NHDF (Normal human dermal fibroblasts)
primary cultures were purchased from PromoCell (Heidelberg,
Germany. HA-SMC and HC-SMC (human normal smooth
muscle cells) primary cultures were purchased from ScienCell
Research Laboratories (Carlsbad, CA). All cells were maintained
and cultured as per suppliers’ recommendations.
Withaferin-A (WFA) was purchased from Chromadex (Irvine,
CA). For in vitro studies the drug was dissolved in DMSO and
stored in 220uC; for in vivo experiments stock solutions were
freshly prepared. The Caspase inhibitor Z-VAD was purchased
from Promega (Madison, WI); the inhibitor was dissolved in
DMSO and stored in 220uc. Commercially available antibodies
were used for immunoblot or immunohistochemical detection of:
caspase-3, cleaved caspase-3, cleaved PARP, AKT, phospho-
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Vimentin (V9), b actin (Santa Cruz Biotechnology, Santa Cruz,
CA); PCNA (DAKO A/S, Copenhagen, Denmark); CD31-
PECAM-1 (PharMingen, San Diego, CA); peroxidase-conjugated
goat anti-rat IgG (Jackson Research Laboratories, West Grove,
CA); peroxidase-conjugated rat anti-mouse IgG2a (Serotec,
Indianapolis, IN). Stable 3,39-diaminobenzidine (Research Genet-
ics, Huntsville, AL) and Gill’s hematoxylin (Sigma, St. Louis, MO)
were used for visualization of IHC reaction and counterstaining,
respectively. TUNEL was performed using a commercial
apoptosis detection kit (Promega Corp., Madison, WI). Additional
reagents are described below.
Cell growth assays
MTS assays: these were conducted using CellTiter96 Aqueous
Non-Radioactive Cell Proliferation Assay kit (Promega Corp,
Madison, WI), per manufacturer’s instructions. Absorbance was
measured at a wavelength of 490 nm, and the absorbance values
of treated cells are presented as a percentage of the absorbance of
untreated cells. Drug concentrations required to inhibit cell growth
by 50% (IC50) were determined by interpolation of dose-response
curves. Colony formation assay: Soft tissue sarcoma cells were
treated in culture dishes for 24 h with DMSO (control) and WFA
(0.5 mM). One hundred viable cells per well were re-plated and
allowed to grow in normal medium for 10 days and then stained
for 30 min at room temperature with a 6% glutaraldehyde, 0.5%
crystal violet solution. Pictures were captured digitally and colonies
were counted. Anchorage independent growth: STS cells were
treated with DMSO (control) or WFA (0.5 mM) for 24 h in a 6-
well plate. 1610
3 viable cells were plated in a 24-well plate in
culture medium containing 0.35% agarose overlying a 0.7%
agarose layer. Cells were incubated for 3 weeks at 37uC. Cells were
stained with p-iodonitrotetrazolium violet (1 mg/ml) for 24 h at
37u. Number of colonies per well were counted. All experiments
were repeated 4 times for each cell line.
Apoptosis assays
Apoptosis was measured using the Apoptosis Detection kit I (BD
Biosciences) per manufacturers’ recommendations. As a standard,
1610
6/mL of cells per treatment condition were fixed and stained
with 5 mL Annexin V–FITC (BD PharMingen, San Diego, CA)
and 5 mL propidium iodide (Sigma, St Louis, MO). Flow
cytometric analysis was performed for 1610
4 cells and analyzed
by FACScan (Becton Dickinson, Franklin Lakes, NJ) using a single
laser emitting excitation light at 488 nm. Data were analyzed by
CellQuest software (Becton Dickson, Franklin Lakes, NJ). To
determine apoptosis in cells grown in suspension (Anoikis),
5610
5 cells/ml SKLMS1 and NHDF cells were placed in 15 ml
conical tubes with filter caps in a total volume of 8 ml complete
DMEM/F12 media, and tubes were placed in a continuous
rotator in a cell culture incubator with and without WFA (1 mM).
After 24 h, 1610
6/mL of cells per treatment condition were fixed
and subjected to Annexin V/PI FACS as per above.
Western blot analysis
Western blot analysis was performed by standard methods.
Briefly, 25 to 50 mg of total proteins extracted from cultured cells
were separated by SDS-PAGE and transferred onto nitrocellulose
membranes. In case of vimentin, extracted proteins represent both
the soluble and polymeric fractions. To further determine
expression levels of soluble and insoluble, polymerized vimentin,
cells were washed with cold PBS before lysis in a buffer containing
1% Triton X-100 (150 mM NaCl, 50 mM Tris, pH 7.4, 10%
glycerol, 1 mM EGTA, 10 mM NaF, 2 mM Na3VO4, 1 mM
PMSF, and protease inhibitor cocktail). Lysate was transferred into
centrifuge conical tubes (Beckman) after incubation on ice for
1 hour. Cells were then centrifuged at 200,000 g for 30 min.
Supernatants (soluble vimentin) were transferred into new tubes,
mixed with 5X sample buffer (312.5 mM Tris, pH 6.8, 50%
glycerol, 10% SDS, 25% 2-mercaptoethanol and 0.25% bromo-
phenol blue). The remaining pellets (insoluble vimentin) were
denatured in Laemmli sample buffer (62.5 mM Tris, pH 6.8, 25%
glycerol, 2% SDS, 5% 2-mercaptoethanol and 0.05% bromophe-
nol blue). All samples were boiled for 10 min before separation on
a 10% SDS PAGE. Membranes were blocked and blotted with
relevant antibodies. HRPconjugated secondary antibodies were
detected by enhanced chemiluminescence (Amersham Biosciences,
Pittsburgh, PA). IRdye680-conjugated and IRdye800-conjugated
secondary antibodies (Molecular Probes) were detected using
Odyssey Imaging (LICOR Biosciences, Lincoln, NE).
Reverse transcription-PCR
RT-PCR was done as previously described [95]. Briefly, total
RNA was isolated from cells using TRIzol reagent (Invitrogen,
Carlsbad, CA) as per manufacturer instructions. Total RNA was
reverse-transcribed using superscript II reverse transcriptase
(Invitrogen, Carlsbad, CA), and 2 uL of the product were used
as templates for multiplex PCR containing both target vimentin
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) prim-
ers for normalization. PCR primers were designed using primer 3
software: vimentin, 59-TCCAGCAGCTTCCTGTAGGT-39 and
59-CCCTCACCTGTGAAGTGGAT- 39; GAPDH, 59-GAGC-
CACATCGCTCAGAC-39and 59-CTTCTCATGGTTCACAC-
CC-39. PCR consisted of denaturation for 3 min at 94uC, 28
cycles of denaturation for 30 s at 94uC, annealing for 40 s at 56uC,
and an extension for 50 s at 72uC. PCR cycles were terminated by
an extension at 72uC for 7 min and products were resolved on a
2% agarose gel.
Transmission electron microscopy
SKLMS1 and STS26T cells were grown on glass coverslips and
treated with WFA or DMSO alone for 4 h (5 mM) or 24 h (1 mM)
and then fixed with a solution containing 3% glutaraldehyde plus
2% paraformaldehyde in cacodylate buffer (pH 7.3) for 1 h. After
fixation, the samples were washed and treated with 0.1%
Millipore-filtered cacodylate-buffered tannic acid, postfixed with
1% buffered osmium tetroxide for 30 min, and stained en-bloc with
1% Millipore-filtered uranyl acetate. The samples were dehydrat-
ed in increasing concentrations of ethanol, infiltrated, and
embedded in Spurr’s low viscosity medium. The samples were
polymerized in a 70uC oven for 2 days. Ultra-thin sections were
cut in a Leica Ultracut microtome (Leica, Deerlake, IL), stained
with uranyl acetate and lead citrate in a Leica EM Stainer, and
examined in a JEM-1010 transmission electron microscope (JEOL
USA Inc., Peabody, MA) at an accelerating voltage of 80 kV.
Digital images were obtained using AMT Imaging System
(Advanced Microscopy Techniques, Danvers, MA).
Migration and invasion assays
Migration and invasion assays were conducted as described
previously [96]. In brief, 2610
5 Cells were plated in a 6-well plate
and treated for 4 h with WFA (0.5 mM) or DMSO. The drug was
washed with PBS and the cell monolayers were carefully wounded
with a 200 uL pipette tip. The cells were photographed after 6 h
utilizing a light microscope. BioCoat cell culture inserts and
polycarbonate filters with 8-mm pores (Becton Dickinson Labware,
Franklin Lakes, NJ) in 24-well tissue culture plates were used for
modified Boyden chamber migration assays. Lower chamber
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serum albumin or 1% fetal bovine serum as chemoattractants.
Cells (5610
4) after 4 hr treatment with WFA (0.5 mM) were
seeded in the upper compartment and incubated at 37uCi na
humidified atmosphere of 95% air and 5% CO2. Invasion assays
were conducted similarly using 24-well BioCoat Matrigel invasion
chambers with 8-mm pore size polycarbonate filters coated with
Matrigel (Becton Dickinson Labware, Franklin Lakes, NJ). After
incubation, filters were fixed with 4% formaldehyde and stained
with 0.2% crystal violet (Baxter Healthcare, Houston TX). Cells
on the upper surface of the filters were removed by wiping with a
cotton swab, and migratory and invasive activities were deter-
mined by counting the number of cells per high-power field (6200)
that had migrated to the lower side of the filter.
Constructs and transfection procedures
Wild-type human vimentin cDNA (pcDNA3-VIM) was a gift
from Dr. Vincent Cryns (Northwestern University, Chicago, IL).
Site-directed mutagenesis was performed according to the
manufacturer’s protocol (Stratagene, Cedar Creek, TX) to replace
aspartic acid-85 and aspartic acid-259 (vimentin caspase cleavage
sites) with aspargine (VIMD85N/D259N). All constructs were
confirmed by DNA sequencing. On-TARGET plus SMARTpool
siRNA constructs targeting vimentin (cat. no. L-003551-00), as
well as non-targeting siRNA, were purchased from Dharmacon
(Lafayette, CO). Anti-vimentin antisense phosphorodiamidate
Morpholino oligomers targeting the splicing junction between
the first exon and second intron of human vimentin pre-mRNA
(sequence, TTGCATGGGCGCAGCCTTACTTCTC) were
purchased from Gene Tools (Philomath, OR).
Plasmid DNA and siRNA were introduced into cells using
Lipofectamine 2000 (Invitrogen) per manufacturer instructions.
Briefly, 2610
5 cells were plated in each well of a six-well plate and
incubated overnight. Cells were then incubated with a mixture of
plasmid DNA (4 mg) or siRNA (20–80 nM) and Lipofectamine
2000 (10 ml) diluted in Dulbecco’s modified Eagle medium
(DMEM) for 24 h, followed by incubation in regular medium.
Cells were harvested at indicated time points for specific
experiments. Anti-vimentin morpholino oligos and standard
non-targeting control morpholino oligos were delivered into cells
by Endo-Porter delivery reagent per manufacturer’s protocol
(Gene Tools). Briefly, 3610
5 cells plated in each well of a six-well
plate were incubated overnight with regular culture medium. The
medium was then replaced with fresh medium containing
morpholino oligos (10 mM). After thorough mixing, Endo-Porter
reagent (12 ml) was added. Cells were harvested for further studies
at indicated time points.
NF-kB reporter assay
The NF-kB dual-luciferase reporter plasmid was purchased
from SABioscience (Fredrick, MD) and the procedure was
conducted based on manufacture’s instructions. STS cells
(parental or 24 hr after anti-vimentin siRNA or non-targeting
siRNA transfection) were first transfected with the reporter
plasmid using sureFECT reagent (SABioscience). After 24–48 hr
cells were further treated with WFA or DMSO prior to lysis with
passive lysis buffer (Promega, Madison, WI). Lysates were
analyzed using the Dual-Glo Luciferase reporter assay system kit
(Promega, Madison, WI). Luminescence was measured by a
programmed DTX multimode detector (Beckman Coulter).
Promoter activity values were measured as arbitrary units using
a renilla reporter for internal normalization and were reported as
relative luciferase activity as compared to control untreated
samples. All experiments were performed in triplicates and the
standard deviation was calculated.
Gelfoam angiogenesis assay
These experiments were approved by the MD Anderson Cancer
Center Institutional Animal Care and Usage Committee. Gel-
foam sponges (Pharmacia & Upjohn, Peapack, NJ) were cut into
approximately 0.560.5 cm square fragments and saturated
overnight in PBS at 4uC. The next day, the sponges were placed
on sterile filter paper to allow excess PBS to be drawn out. Sponges
were incubated with conditioned media from SKLMS1 cells. The
sponges were allowed to sit at room temperature for approxi-
mately 1 hour and then implanted subcutaneously into the flank of
SCID mice (n=8), as previously described [97]. Mice were
assigned to two treatment groups: WFA (2 mg/kg/once daily) vs.
DMSO (control group). After ten consecutive treatment days the
gel-foam sponges were harvested and frozen in OCT (Sakura
Fineter, Torrance, CA). The frozen samples were later sectioned
and probed for CD31 and TUNEL.
In vivo animal models
All animal procedures and care were approved by the MD
Anderson Cancer Center Institutional Animal Care and Usage
Committee. Animals received humane care as per the Animal
Welfare Act and the NIH ‘‘Guide for the Care and Use of
Laboratory Animals.’’ Animal models were utilized as previously
described [98]. Trypan blue staining confirmed viable STS cells
(SKLMS1 and HT1080 1610
6/0.1 mL HBSS/mouse) were
injected subcutaneously into the flank of six week old female
SCID mice (n=20/experiment), growth was measured twice
weekly; after establishment of palpable lesions mice were assigned
to two treatment groups (10 mice per group): control (vehicle only)
and WFA, i.p. (2 mg/kg/day). Mice were followed for tumor size,
well being, and body weight and sacrificed when control group
tumors reached an average of 1.5 cm in their largest dimension.
Tumors were resected, weighed, and frozen or fixed in formalin
and paraffin-embedded for immunohistochemical studies.
To evaluate the effect of WFA on STS local recurrence,
SKLMS1 cells (1610
6/0.1 mL HBSS/mouse) were injected
subcutaneously into the flank of female SCID mice (n=15).
Tumors were left to grow until they reached an average of 1.5 cm
at their largest dimension at which time they were resected within
their pseudo-capsule, thus mimicking a complete macroscopic
resection with positive microscopic margins. Two days after
surgical procedure mice were allocated to two treatment groups as
per above and were monitored for tumor recurrence.
An experimental lung metastasis STS model was used to
evaluate metastases growth. STS26T cells (1610
6/0.1 mL HBSS/
mouse) were injected into the tail vein of female SCID mice
(n=20). Ten days after injection (a time-point by which 95–100%
of mice develop established lung metastases) mice were allocated
to two treatment groups as per above. Mice were followed for
body weight and well being and sacrificed after two weeks of
treatment. Lungs were resected, evaluated macroscopically for
tumor load, weighed, and fixed in formalin and paraffin-
embedded for immunohistochemical studies.
Immunohistochemistry and TUNEL assays
Immunohistochemistry, immunoflorescence, double immuno-
florescence, and TUNEL assays were performed as previously
described [99]. Staining scoring was conducted by 2 independent
reviewers (GL and AJL). PCNA scoring was determined as the
average of the percent of positive immunoreactive cells evaluated
by counting tumor cells in 5 high-power fields (x400). For TUNEL
WFA Induces Vimentin Cleavage
PLoS ONE | www.plosone.org 16 April 2010 | Volume 5 | Issue 4 | e10105scoring, the average number of positive nuclei was calculated in 5
high-power microscopic fields (x400) selected from a central region
in viable tumor areas, avoiding areas containing necrosis. Five of
the most vascularized areas within a tumor (‘‘hot spots’’) identified
based on CD31 positivity were chosen at low magnification and
vessels were counted in a representative high-power (x400) field in
each of these areas. Blood vessel density was calculated as the
summation of all counts divided by 5.
Statistics
Cell culture-based assays were repeated at least 3 times and
mean 6 SD was calculated. Cell lines were examined separately.
For outcomes that were measured at a single time point, two-
sample t-tests were used to assess the differences. Differences in
xenograft growth (tumor/metastases) in vivo were assessed using a
two-tailed Student’s t-test. Significance was set at P#0.05.
Supporting Information
Data S1 Supplemetal Materials and Methods
Found at: doi:10.1371/journal.pone.0010105.s001 (0.04 MB
DOC)
Figure S1 Isolation and characterization of the human pleo-
morphic liposarcoma cell line PLS1. A) H+E staining of original
human tumor; B) PLS-1 cells morphology in culture; C) PLS1 cells
exhibit anchorage independent growth; D) PLS-1harbor an
aneuploid karyotype; E) G-banding reveals complex karyotype;
F) PLS1 cells grow as xenografts in SCID mice, histomorphology is
similar to that of the original human tumor.
Found at: doi:10.1371/journal.pone.0010105.s002 (0.10 MB
PDF)
Figure S2 WFA induced morphological changes in human STS
and vimentin- expressing epithelial cancer cell lines.
Found at: doi:10.1371/journal.pone.0010105.s003 (0.10 MB
PDF)
Figure S3 Human intestinal smooth muscle cells (HC-SMC) are
more resistant to the effects of WFA as compared to STS cells.
Graphs represent the average of three repeated experiments 6SD.
Found at: doi:10.1371/journal.pone.0010105.s004 (0.05 MB
PDF)
Figure S4 WFA abrogates STS cell migration and invasion. A)
Wound healing scratch assays demonstrating the effect of WFA on
STS cell migration; B) modified Boyden chamber assays depicting
the inhibitory effects of WFA on STS cell migration and invasion.
Graphs represent the average of three repeated experiments 6SD.
Found at: doi:10.1371/journal.pone.0010105.s005 (0.20 MB
PDF)
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